CMV Vaccine shows promise
SAN DIEGO, Oct. 7, 2009 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) announced today that the company's TransVax(TM) cytomegalovirus (CMV) vaccine continued to demonstrate an overall increase in cellular immune responses compared with placebo at the seven-month immunogenicity data point in an ongoing Phase 2 trial. Alain P. Rolland, Pharm.D., Ph.D., Vical's Executive Vice President of Product Development, presented the data today at the World Vaccine Congress (Lyon, France - October 5-8).
"T-cell responses are very important in protecting recovering transplant recipients against CMV disease," said Dr. Rolland, "and we were pleased to see that the T-cell responses to both CMV antigens encoded by our vaccine, noted in our four-month interim analysis, were sustained through the seven-month data point. In addition, we saw a promising emerging trend in the antibody response against CMV after the last of four scheduled injections. We look forward to reviewing the final trial data in the first half of 2010."
[ Posted on Saturday October 17 - 9:52 pm ]
Latest news
The question was, 'What would Tom do?'
From the Toronto Star May 6, 2010
It's a difficult question to ask a mother. And, you might think, impossible to answer:
How do you cope with the death of not just one, but two, o...
[ More... ]
OETSG Bike Donation to TGH
OETSG presented a cheque for $6000 to the Transplant Unit Treadmill Room at Toronto General Hospital. The money was used to buy a bike for physiotherapy and an Oxometre to monitor pre/post transplant recipients while th...
[ More... ]
65_REDROSES on CBC
65_REDROSES will Premiere on THE PASSIONATE EYE on CBC News Network (formerly CBC Newsworld) on Monday, Nov.16 at 10pm ET/PT.
For 23-year old Canadian Eva Markvoort (aka 65_redroses, her online pseudonym), the clock i...
[ More... ]